Tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma compared to entecavir in patients with chronic hepatitis B

Abstract

A paper published several years ago suggested that tenofovir disoproxil fumarate (TDF) was superior to entecavir (ETV) for reducing the risk of hepatocellular carcinoma (HCC). Since then, many observational studies have been conducted comparing TDF and ETV. Many studies in Asia demonstrated similar HCC risks between ETV and TDF groups. Similarly, recent studies involving Caucasian and European did not observe any differences in HCC risk between these groups. In this article, we briefly review studies that compared the incidence rates of HCC between ETV and TDF and discuss potential reasons for the discrepant results.

Keywords

Hepatitis B / entecavir / tenofovir / hepatocellular carcinoma

References

[1] Wong GL,Mak CW.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.Hepatology2013;58:1537-47

[2] Liu K,Le A.Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.Aliment Pharmacol Ther2019;50:1037-48

[3] Choi J,Lim YS.Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.Hepatology2021;73:661-73

[4] Choi J,Lee J,Ko MJ.Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study.JAMA Oncol2019;5:30-6 PMCID:PMC6439769

[5] Choi WM,Lim YS.Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2021;19:246-58.e9

[6] Yip TC,Chan HL,Lui GC.Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China.Gastroenterology2020;158:215-25.e6

[7] Kim SU,Lee HA.A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.J Hepatol2019;71:456-64

[8] Lee SW,Lee HL.Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.Gut2020;69:1301-8 PMCID:PMC7306978

[9] Oh H,Jun DW.Long-Term Safety of Entecavir and Tenofovir in Patients With Treatment-Naive Chronic Hepatitis B Virus (CHB) Infection (SAINT) StudyNo difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir.Clin Gastroenterol Hepatol2020;18:2793-802.e6

[10] Tseng C,Chen T.Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:1039-52

[11] Papatheodoridis GV,Idilman R.Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.J Hepatol2020;73:1037-45

[12] S; ANRS/AFEF study group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.Aliment Pharmacol Ther2021;53:616-29

[13] Lee JH,Park SY.The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.Eur J Intern Med2021;89:48-55

[14] Lee SW,Kim SU.Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.Clin Mol Hepatol2021;27:402-12 PMCID:PMC8273642

[15] Papatheodoridis G,Yurtaydin S.Prediction and need for surveillanceof hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort.2018;